Statistical Sampling in FCA Cases: Where Courts Draw Limits

The government and qui tam relators increasingly build False Claims Act cases by reviewing a sample of disputed claims and applying statistical sampling and extrapolation to the full claim universe. When a Medicare Administrative Contractor or the Department of Justice extrapolates a finding from a few hundred reviewed claims across tens of thousands billed, a modest per-claim error rate can produce a demand in the millions once trebled. Whether sampling can prove claims were false in the first place, rather than size damages once falsity is already established, is where courts have drawn the sharpest limits.

Sampling Proves Liability, Not Just Damages

Extrapolation has functioned for decades as a damages tool: once liability is established, a sample can reasonably size the total overpayment or trebled damages across a lookback period. The shift over the last decade has been toward using sampling to prove liability itself, before any claim is individually adjudicated as false. In United States ex rel. Martin v. Life Care Centers of America (E.D. Tenn. 2014), the court permitted the government to draw a random sample of 400 patient admissions from more than 154,000 Medicare claims across 82 skilled nursing facilities, and to extrapolate a falsity finding across the entire claim set, finding claim-by-claim litigation impracticable at that scale. The sampling was admissible so long as it was representative and the methodology sound.

Where Courts Have Drawn the Line

Life Care Centers is not the last word. In United States ex rel. Wall v. Vista Hospice Care (N.D. Tex. 2016), the court rejected a sample of 291 hospice patient files extrapolated to roughly 12,000 claims, holding that hospice eligibility turns on individualized clinical judgment a sample cannot substitute for. The Eleventh Circuit reached a related conclusion in United States ex rel. Paradies v. AseraCare (11th Cir. 2019): a reasonable disagreement among physicians reviewing the same record does not, alone, establish an objectively false claim, and cannot support liability across a sampled population. The Fourth Circuit never reached the merits in United States ex rel. Michaels v. Agape Senior Community (4th Cir. 2017), a relator-driven action addressed in How a Qui Tam Lawsuit Unfolds: From Sealed Complaint to Intervention; the court dismissed the interlocutory appeal, leaving the sampling restriction in place without a nationwide rule. A related but separate defense, the materiality standard after Escobar, is covered in The Materiality Defense After Escobar.

A sample proves only what the claims inside it prove. Whether it can stand in for every claim outside it depends on whether those claims are alike enough for one answer to cover them all.

Building the Defense Record Against Extrapolation

The defense record that has actually moved outcomes attacks three things: whether the claims sampled are similar enough to represent the whole, whether the sample was large enough and randomly selected, and whether the methodology holds up under Federal Rule of Evidence 702. In United States v. Krizek (D.C. Cir. 1997, 1999), the government extrapolated liability across more than 8,000 claims and sought $81 million in penalties. After claim-by-claim review on remand, only three claims held up, and the final judgment came to $77,105.39, a fraction of the original demand. The per-claim penalty math behind that exposure is explained in False Claims Act Damages and Per-Claim Penalties. Medicare audits apply a parallel check: a Medicare Administrative Contractor may not extrapolate an overpayment unless CMS has found a sustained or high level of payment error, or documented education has failed, under 42 U.S.C. § 1395ddd(f)(3). Representativeness, sample size, and methodology are the same three questions whether the audit sits in an administrative appeal or in FCA litigation.

Why Early Legal Counsel Is Critical

It is critical that healthcare providers promptly retain healthcare defense counsel upon receiving a Civil Investigative Demand, a qui tam complaint, an audit notice invoking extrapolation, or another government inquiry. Early legal intervention can protect the provider's rights, help frame the record before a sample is drawn, avoid inadvertent admissions about billing practices still in dispute, preserve relevant defenses, and allow counsel to communicate with investigators and auditors on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter, including whether an extrapolated demand is ever meaningfully challenged.

How Health Law Alliance Can Help

Health Law Alliance represents pharmacies, physicians, and healthcare companies facing False Claims Act matters built on statistical sampling and extrapolated damages. We review the claim population for the representativeness and methodology a sample depends on, challenge extrapolation under Federal Rule of Evidence 702 where the sample cannot support its conclusions, and shape settlement positions around what a claim-by-claim record would show. If your pharmacy or practice has received a Civil Investigative Demand, a qui tam complaint, or an audit notice invoking extrapolation, contact us for a free, confidential consultation.